EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 3.0

Optimizing the efficiency of therapeutic HIV vaccine trials: A case for CTN 173

Johanna N. Spaans, Jean-Pierre Routy, Cécile Tremblay, Joel Singer, Nicole Bernard, Sanjay Gurunathan, Rafick-Pierre Sékaly, Jonathan B. Angel

Trials in Vaccinology · 2012

DOI: 10.1016/j.trivac.2012.01.003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Trials in Vaccinology, 2012. Verfasst von Johanna N. Spaans und 7 weiteren Autor:innen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The introduction of highly active antiretroviral therapy (HAART) has enabled the dramatic reduction in viral replication and the partial restoration of host immune function, albeit at the expense of drug toxicity. Strategies to enhance HIV-specific immunity are required in order to limit ART exposure. Therapeutic vaccination is a promising new approach to enhance immunogenicity and anti-viral activity in people infected with HIV. Efficient clinical trial designs are required to optimize therapeutic HIV vaccination strategies. Herein, we describe unique design features and investigational procedures that were applied to a prime-boost therapeutic vaccine trial (CTN 173) to enhance HIV immunity. CTN 173 was a multicentre, randomized, 3-arm, double-blind placebo controlled trial to evaluate anti-viral activity of therapeutic vaccination with ALVAC ± Remune in chronically infected individuals on HAART. CTN 173 was developed with the specific aim to better characterize patient factors and immunologic parameters associated with vaccine response. This paper discusses the relevance of choice of primary endpoint and statistical approach used in this trial, in relation to vaccine response, patient safety and the identification of optimal target populations for future vaccine trials. Time to event surrogate endpoints of viral response and frequent immunologic monitoring allow for a better characterization of immunologic correlates of vaccine response. The clinical implications of delayed viral rebound associated with therapeutic vaccination with ALVAC + Remune are not yet known and will need to be evaluated on long-term follow-up. Randomized controlled trials such as CTN 173, with well-defined surrogate endpoints and frequent immunologic and virologic monitoring, are necessary to streamline the approach to effective vaccine discovery and to ensure patient safety.

Zitieren

APA

Spaans, J. N., Routy, J., Tremblay, C., Singer, J., Bernard, N., Gurunathan, S., Sékaly, R., & Angel, J. B. (2012). Optimizing the efficiency of therapeutic HIV vaccine trials: A case for CTN 173. Trials in Vaccinology. https://doi.org/10.1016/j.trivac.2012.01.003

Vancouver

Spaans JN, Routy J, Tremblay C, Singer J, Bernard N, Gurunathan S, et al. Optimizing the efficiency of therapeutic HIV vaccine trials: A case for CTN 173. Trials in Vaccinology. 2012. doi:10.1016/j.trivac.2012.01.003

BibTeX
@article{Spaans2012,
  author = {Spaans, Johanna N. and Routy, Jean-Pierre and Tremblay, Cécile and Singer, Joel and Bernard, Nicole and Gurunathan, Sanjay and Sékaly, Rafick-Pierre and Angel, Jonathan B.},
  title = {Optimizing the efficiency of therapeutic HIV vaccine trials: A case for CTN 173},
  journal = {Trials in Vaccinology},
  year = {2012},
  doi = {10.1016/j.trivac.2012.01.003}
}
Kostenlos starten →